ADVISORY, Feb. 27, 2014 (GLOBE NEWSWIRE) --
Amicus Therapeutics, Inc. [FOLD], a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, will visit the NASDAQ MarketSite in Times Square in celebration of Rare Disease Day(R) 2014. Rare Disease Day is held the last day of February each year and is the occasion to raise awareness for rare diseases. Amicus will be joined by representatives from several patient advocacy organizations including the Global Genes Project, the National Organization for Rare Disorders, the Acid Maltase Deficiency Association, the Fabry Support and Information Group, the National MPS Society, the Histiocytosis Association, the National Fabry Disease Foundation, the National Gaucher Foundation, the National Tay-Sachs & Allied Diseases Association, Jonah Has Just Begun and the United Pompe Foundation.
In honor of the occasion, John Crowley, Chairman and CEO of Amicus will ring the Closing Bell.
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Friday, February 28, 2014 – 3:45 p.m. to 4:00 p.m. ET
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq.
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.
For exciting viral content and ceremony photos visit our Tumblr Page: http://nasdaq.tumblr.com/.
A LiveStream of the NASDAQ Closing Bell will be available at: https://new.livestream.com/nasdaq/live
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Amicus Therapeutics, Inc. [FOLD]:
Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.
About NASDAQ OMX Group:
NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,300 listed companies with a market value of over $8 trillion. To learn more, visit www.nasdaqomx.com.
Source:The NASDAQ OMX Group, Inc.